Menu
 
Research menu
Jump to menu

Publications:  Dr David Holden

Holden DW, Gold J, Hawkes CH, Giovannoni G, Saxton JM, Carter A, Sharrack B(2018). Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. Mult Scler Relat Disord vol. 25, 197-199.
10.1016/j.msard.2018.07.041
Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al.(2018). A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple Sclerosis and Related Disorders vol. 24, 123-128.
10.1016/j.msard.2018.06.002
https://qmro.qmul.ac.uk/xmlui/handle/123456789/42250
Gold J, Marta MC, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 188-189.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25994
Marta M, MacManus D, Yousry T, Miller D, Altmann DR, Meier UC, Christensen T, Maruszak H et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 188-188.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25993
Gold J, Giovannoni G, Marta MC, Meier U, Miller D, Christensen T, Maruszak H, Holden D et al. (2015). Pilot baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 162-162.
Maghzi AH, Meier U, Holden D, Marta M, Kantor A, Waubant E, Giovannoni G, Goelz S (2009). Natural killer cell status in multiple sclerosis and its association with interferon beta-1a treatment. MULTIPLE SCLEROSIS. vol. 15, S73-S73.
Return to top